Vertex bets $10B on Crinetics to reshape endocrinology portfolio

1 min read
Source: Endpoints News
Vertex bets $10B on Crinetics to reshape endocrinology portfolio
Photo: Endpoints News
TL;DR Summary

Vertex Pharmaceuticals agreed to acquire Crinetics Pharmaceuticals for $10 billion, marking the largest deal in Vertex’s history and expanding its commercial endocrinology portfolio with Crinetics’ programs in obesity, diabetes and related endocrine diseases.

Share this article

Reading Insights

Total Reads

1

Unique Readers

8

Time Saved

3 min

vs 4 min read

Condensed

95%

61133 words

Want the full story? Read the original article

Read on Endpoints News